Reactivation of hepatitis B two years after rituximab therapy in a renal transplant patient with recurrent focal segmental glomerulosclerosis: a note of caution

被引：14

作者：

Gossmann, Jan ^{[1
,2
]}

Scheuermann, Ernst-Heinrich ^{[2
]}

Kachel, Heinz-Georg ^{[1
]}

Geiger, Helmut ^{[2
]}

Hauser, Ingeborg A. ^{[2
]}

机构：

[1] KfH Nierenzentrum, D-60528 Frankfurt, Germany

[2] Univ Frankfurt Klinikum, Med Klin 3, D-6000 Frankfurt, Germany

来源：

CLINICAL TRANSPLANTATION | 2009年 / 23卷 / 03期

关键词：

hepatitis B; kidney transplantation; reactivation; renal transplantation; rituximab; VIRUS REACTIVATION; CYTOTOXIC CHEMOTHERAPY; PREEMPTIVE LAMIVUDINE; ANTI-HBS; ANTIBODIES; MANAGEMENT; REMISSION; LYMPHOMA;

D O I：

10.1111/j.1399-0012.2008.00936.x

中图分类号：

R61 [外科手术学];

学科分类号：

摘要：

We report on the reactivation of hepatitis B in a renal transplant patient who had been treated with rituximab for recurrent focal segmental glomerulosclerosis two and a half yr previously. He lost his anti-hepatitis B surface antigens and anti-hepatitis B core antigen antibodies and developed hepatitis B Virus (HBV)-DNA positive hepatitis. Hepatitis C, which had been successfully treated by alpha interferon 10 yr before, remained quiescent. We suggest regular controls of HBV-DNA, anti-HBV antibodies and transaminases for prolonged periods in patients with status post-hepatitis B treated with rituximab. Prophylactic therapy with lamivudine and/or hepatitis B hyperimmune globulin may be considered in patients with a decrease in anti-HBV antibodies.

引用

页码：431 / 434

页数：4

共 29 条

[1]

Ahmed A, 1999, AM J GASTROENTEROL, V94, P249, DOI 10.1111/j.1572-0241.1999.00808.x

[2] The management of chronic hepatitis B in the immunocompromised patient: Recommendations from a single topic meeting [J].

Barclay, Stephen ;

Pol, Stanislas ;

Mutimer, David ;

Benhamoud, Yves ;

Mills, Peter R. ;

Hayes, Peter C. ;

Cameron, Sheila ;

Cameron, William .

JOURNAL OF CLINICAL VIROLOGY, 2008, 41 (04) :243-254

[3]

Barclay Stephen, 2008, J Clin Virol, V42, P104, DOI 10.1016/j.jcv.2008.03.021

[4] Rituximab as treatment for refractory kidney transplant rejection [J].

Becker, YT ;

Becker, BN ;

Pirsch, JD ;

Sollinger, HW .

AMERICAN JOURNAL OF TRANSPLANTATION, 2004, 4 (06) :996-1001

[5] Change of the course of steroid-dependent nephrotic syndrome after rituximab therapy [J].

Benz, K ;

Dötsch, J ;

Rascher, W ;

Stachel, D .

PEDIATRIC NEPHROLOGY, 2004, 19 (07) :794-797

[6] Reactivation of hepatitis B after transplantation in patients with pre-existing anti-hepatitis B surface antigen antibodies - Report on three cases and review of the literature [J].

Blanpain, C ;

Knoop, C ;

Delforge, ML ;

Antoine, M ;

Peny, MO ;

Liesnard, C ;

Vereerstraeten, P ;

Cogan, E ;

Adler, M ;

Abramowicz, D .

TRANSPLANTATION, 1998, 66 (07) :883-886

[7] Delayed hepatitis B virus reactivation after cessation of preemptive lamivudine in lymphoma patients treated with rituximab plus CHOP [J].

Dai, MS ;

Chao, TY ;

Kao, WY ;

Shyu, RY ;

Liu, TM .

ANNALS OF HEMATOLOGY, 2004, 83 (12) :769-774

[8] Preemptive use of lamivudine in breast cancer patients carrying hepatitis B virus undergoing cytotoxic chemotherapy: a longitudinal follow-up [J].

Dai, MS ;

Wu, PF ;

Lu, JJ ;

Shyu, RY ;

Chao, TY .

SUPPORTIVE CARE IN CANCER, 2004, 12 (03) :191-196

[9]

Dhédin N, 1998, TRANSPLANTATION, V66, P616

[10] Is hepatitis B immunoglobulin prophylaxis needed for liver transplantation in the era of new antivirals? [J].

Egwim, C ;

Botero, RC .

TRANSPLANTATION PROCEEDINGS, 2005, 37 (05) :2200-2204

← 1 2 3 →